Articles tagged with Prostate Cancer
Researchers have found a link between prostate cancer aggressiveness and cholesteryl ester accumulation, suggesting new diagnostic and treatment methods. The study also shows that drugs previously developed to treat atherosclerosis might be repurposed for advanced prostate cancer treatment.
Researchers found higher levels of BPA in prostate cancer patients than non-prostate cancer patients, with low-dose exposure linked to centrosome amplification and cell transformation. The study suggests a previously unknown relationship between BPA exposure and prostate cancer development.
The PROCEDE 500 study demonstrates that the Prolaris test provides personalized risk assessment for prostate cancer patients, leading to significant changes in treatment plans. The study found a 50% reduction in surgical interventions and a 30% reduction in radiation treatment.
Patient satisfaction with treatment is greater when outcome information is specific to their treating physician, according to a study. This type of information helps patients set realistic expectations and make informed decisions about therapy selection.
A UCLA study published in European Urology found that robotic-assisted prostate surgery resulted in 5% fewer positive margins and a one-third reduction in the likelihood of needing additional cancer therapies. This suggests that robotic-assisted radical prostatectomy may offer better cancer control with potentially lower downstream costs.
University of Houston scientists identify AMPK enzyme's role in prostate cancer progression and metabolic changes. Their findings suggest that targeting metabolic pathways could lead to more effective cancer treatments.
The trial found that men treated with the more intensive radiotherapy regime had a 55% survival rate without disease progression, compared to 43%. The study also showed that dose-escalated radiotherapy reduces the need for follow-up hormone treatment and is safe in the long term.
A new study published in JNCI Journal of the National Cancer Institute found that high-dose selenium supplementation increased the risk of high-grade prostate cancer among older men with high baseline toenail selenium concentrations. Vitamin E supplementation also raised PC risk, especially among men with low baseline selenium levels.
A study published in the Journal of the National Cancer Institute found that high-dose supplementation with selenium and vitamin E increases the risk of high-grade prostate cancer in men. The risk depends on a man's baseline selenium level, with men who have low levels experiencing a higher risk
Scientists at The Institute of Cancer Research have discovered that screening for certain genetic mutations in men with a family history of prostate cancer can predict the development of aggressive forms of the disease. The study identified 13 'loss of function' mutations in eight DNA repair genes, which significantly increase the risk...
Researchers discovered that SPOP protein selectively destroys androgen receptor, a master regulator of prostate cancer cell growth. This finding sheds light on a new mechanism by which prostate cancer develops.
Scientists have discovered how the prostate gland develops for the first time, identifying 80 genes and a signalling pathway involved in its growth. The finding provides potential targets for new therapies to combat common prostate diseases, including prostate cancer.
A new study found that 3D mapping biopsies detect nearly three times as many cancerous zones in prostate cancer patients compared to ultrasound-guided biopsies. The study suggests that 3D mapping biopsies can accurately assess the location, stage, and risk of prostate cancer, leading to more targeted treatment options.
Dormant prostate cancer cells in bone tissue can be reactivated to form secondary tumors when exposed to the signaling molecule RANKL. Researchers have discovered that this reactivation process may lead to metastatic prostate cancer in bones, and targeting it could prevent metastasis and improve survival rates.
The PROCEDE 500 clinical utility study demonstrates the significant clinical value of Prolaris to physicians treating men with prostate cancer. The test accurately predicts prostate cancer-specific death and metastases, guiding treatment decisions and reducing therapeutic burden on patients.
Researchers have developed a new mouse model for metastatic prostate cancer, called RapidCaP, which reveals a specific role for Myc as a driver of metastasis in prostate cancer. The study suggests that targeting the Myc gene may provide a new approach to cure incurable prostate cancer.
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, with no significant decline in emotional quality of life two years after treatment. Investigators recommend counseling men about p...
Research suggests that walking at a brisk pace prior to diagnosis may improve prostate cancer outcomes by having more regularly shaped blood vessels. Men with faster walking paces had 8% more regularly shaped blood vessels compared to those with slower paces.
A study of Icelandic men found that higher melatonin levels were associated with a 75% reduced risk for developing advanced prostate cancer. Men who reported sleep problems had lower melatonin levels, suggesting the importance of maintaining a stable sleep-wake cycle.
Researchers at Penn State will receive $651,000 to create a method for identifying a prostate cancer-specific drug and developing a biodegradable nanoparticle capable of targeting the disease. The goal is to create an alternative to chemotherapy with reduced side effects.
A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds strongly onto a particular SNP variant, initiating a genetic programme enhancing prostate cancer proliferation and metastasis. The study used DNA samples from tens of thousands of prostate cancer patients and healthy me...
Researchers developed a nomogram to predict likelihood of overdiagnosis based on age, PSA level, and Gleason score. The tool aims to help patients and clinicians make informed decisions about treatment options.
A study from the University of Illinois Chicago found that fetal exposure to BPA increases the risk for prostate cancer later in life. Human prostate tissue is susceptible to BPA, which mimics estrogen and has been linked to several cancers.
A new nomogram developed by Roman Gulati et al. estimates the likelihood of overdiagnosis for screen-detected prostate cancers, considering patient age, Gleason score, and PSA level at diagnosis. The model predicts risks ranging from 2.9% to 88.1% depending on individual characteristics.
A study published in Oncogene found that androgens hijack the AMPK signaling cascade to increase prostate cancer cell growth. This metabolic switch has significant implications for understanding early and late-stage prostate cancer progression.
Researchers will investigate racial and ethnic differences in IRDS-positive tumors prevalent in African-Americans to improve outcomes for patients with treatment-resistant prostate cancer. The study aims to identify new management and treatment options for this aggressive disease.
A Mayo Clinic-led study found that pain drugs used in prostate gland removal may be linked to cancer outcomes, as they can suppress the immune system's ability to fight cancer cells. The research suggests that a specific technique using opioids may reduce the risk of cancer recurrence and mortality.
A new optical sensor created at MIT can track zinc within cells, shedding light on its functions and helping researchers study zinc trafficking in prostate cells. The sensor supports the theory that cancerous prostate cells banish zinc from mitochondria to produce extra energy.
A study published online in Cancer found that increased inflammation in the prostate gland may predict a reduced risk of developing prostate cancer. The study's findings suggest that biopsies performed on prostates with high inflammation levels may indicate a lower risk for subsequent cancer detection.
Researchers have identified a potential biological factor contributing to racial disparities in prostate cancer incidence and mortality. Advanced glycation end-products (AGEs) accumulate in African-American men with prostate cancer, promoting inflammation and cancer progression. AGE levels correlated with receptor for AGE (RAGE), sugge...
Researchers identified a biomarker for prostate cancer recurrence, revealing that patients with CD151free protein have cancer recur earlier than those without. This discovery may aid in determining patient care and predicting disease progression.
Researchers found that 53% of men with ERG-positive HGPIN biopsies developed invasive prostate cancer, compared to 35% of those with ERG-negative biopsies. The discovery may help physicians monitor men at higher risk for cancer development and reduce unnecessary future biopsies.
A new study found that men with a specific genetic mutation are more than 50% likely to die from prostate cancer if they're overweight or obese. The researchers analyzed data on 1,243 participants and discovered that obesity was linked to higher levels of insulin and growth factor receptors in tumors containing the mutation.
Researchers at Henry Ford's Vattikuti Urology Institute found instances of ureteral injury in 6,442 patients who underwent robotic prostatectomy. Patient characteristics such as infection history, abdominal surgery, and enlarged prostate glands may forewarn such damage.
Men with prostate cancer who followed a low-fat fish oil diet had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score compared to those on a Western diet. The study suggests that altering the diet may favorably affect prostate cancer biology.
Researchers have identified large oncosomes as a potential indicator of patients with more aggressive, treatment-resistant disease. The study also found that microRNA in these vesicles can influence tumor progression.
A new study suggests that treatment of pelvic nodes individualized by including sentinel nodes can be easily integrated into an IMRT-based strategy, correctly covering individual pelvic nodes without nodal recurrence. The study's findings indicate low toxicity and efficacy, justifying further evaluation.
Researchers discovered that selective inhibition of nuclear export protein CRM1 can reactivate tumor suppressor proteins in cells, leading to cancer cell death. This approach shows promise for treating advanced prostate cancers.
Researchers developed predictive models to forecast genito-urinary (GU) toxicity and erectile dysfunction in prostate cancer patients after high-dose radiotherapy. Smoking and dosimetric factors were key predictors of acute urinary symptoms, with the model confirmed by a larger cohort analysis.
Researchers explore genetic and epigenetic factors contributing to racial disparities in prostate cancer risk and progression, focusing on MicroRNAs as potential biomarkers.
Researchers found that geranylgeraniol suppressed human DU145 prostate carcinoma cell viability via cell cycle arrest at the G1 phase and apoptosis initiation. The compound also down-regulated HMG CoA reductase, a key enzyme in the mevalonate pathway.
A Polish study has developed a new imaging modality using Magnetic Resonance Imaging-Ultrasound (MRIUS) to guide prostate biopsies, yielding higher sensitivity rates compared to traditional TRUS biopsies. The technology, which fuses MRI with TRUS images, allows for real-time guidance of targeted biopsies in office settings.
A study published in Physics in Medicine and Biology found that endorectal balloon placement errors can reduce radiation dose coverage, leading to uneven targeting of cancerous areas. Image guidance is crucial to ensure accurate prostate positioning.
A pilot study shows that older patients who practiced Qigong experienced significant declines in fatigue and distress. The mind-body activity, which combines slow movements with deep breathing and meditation, was found to be an effective nonpharmacological intervention for managing prostate cancer-related fatigue.
A Kaiser Permanente study found that men diagnosed with prostate cancer who were overweight or obese at diagnosis were more likely to die from the disease. Men with high Gleason scores had the strongest correlation between body mass index and death, suggesting weight loss could prolong survival.
Researchers tracked lethal prostate cancer to determine the clonal origin of a patient's deadly disease. Using tissue samples, they identified the primary tumor site of the lethal clone, revealing that it originated from a small, low-grade foci rather than the larger high-grade region.
Researchers analyzed genealogical and medical records of Utah males, identifying distinct Y chromosomes associated with a significant excess risk of prostate cancer. The study found that nearly 73 out of 1,000 Y chromosome groups had a higher incidence of prostate cancers than expected.
A comprehensive review of Medicare claims found that nearly all the increase in IMRT for prostate cancer was due to self-referral, leading to unnecessary radiation therapy. Self-referring urologists increased IMRT use by 146%, while non-self-referrers remained unchanged.
A new online program developed by Thomas Jefferson University researchers has shown that more patients choose active surveillance over therapy when presented with pros and cons of treatment options. The program helps patients clarify their treatment preferences and discuss options with the clinical team.
A new study by University of Pennsylvania researcher Robert Aronowitz highlights the flaws in prostate cancer screening measures, citing a 1950s study that showed invasive procedures were often performed without solid evidence. Millions of men have undergone PSA tests, which can lead to unnecessary treatments and detrimental effects.
A study from University of Texas Medical Branch found that more than 40% of men over 75 undergo PSA screening, despite no medical organization recommending it for this age group. The researchers suggest that decision-making by primary care physicians is a major reason for the continued high PSA rate.
A recent study found that detecting changes in circulating tumor cells (CTC) may be more accurate than tracking prostate-specific antigen (PSA) levels to predict treatment outcomes in patients with castration-resistant prostate cancer. The study showed a favorable change in CTC detection occurred in over half of patients during chemoth...
A study by Yale researchers found that Medicare spent $447 million annually on PSA-based screenings for prostate cancer, with most of it going to men over 75. The cost variation was mainly due to follow-up tests, not the use of the PSA itself.
Researchers estimate that routine PSA testing can lead to increased impotence and incontinence cases, as well as additional prostate cancer diagnoses. However, the difference in death rates between screened and unscreened men is relatively small, with only 0.07 more deaths attributed to screening.
Researchers found that men with variable telomere length in cancer cells and shorter telomeres in stromal cells were more likely to develop metastatic disease and die sooner from their prostate cancer. This combination could be a marker for prostate cancer prognosis.
Researchers found that unstable chromosomes with breaks at common fragile sites are associated with a less favorable response to radiation therapy and surgery in prostate cancer patients. These abnormalities are often linked to DNA instability, which is characteristic of cancer cells.
Cancer researchers at UC San Diego isolated and characterized early-stage prostate cancer cells, which may drive recurrent disease. The study suggests that these cells could be targeted for new treatments, potentially reducing cancer progression.
A secondary analysis of the historic RTOG 9202 prostate cancer trial found no additional benefits with long-term hormonal therapy compared to short-term therapy in intermediate-risk patients. The study suggests that administering less treatment can reduce side effects and healthcare costs without compromising survival rates.
A shorter course of androgen suppression therapy prior to radiation therapy yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients. The study confirmed a disease-specific-survival rate of 95 percent when patients received fewer weeks of neoadjuvant total androgen suppression.
A new study by Moffitt Cancer Center aims to investigate alternative screening methods and chemoprevention interventions for African-American and black men with prostate cancer. Researchers are also exploring the safety and effectiveness of isoflavones, a botanical agent, in reducing prostate cancer risk in this high-risk population.